382 related articles for article (PubMed ID: 29066265)
1. Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia.
Hovingh GK; Raal FJ; Dent R; Stefanutti C; Descamps O; Masana L; Lira A; Bridges I; Coll B; Sullivan D
J Clin Lipidol; 2017; 11(6):1448-1457. PubMed ID: 29066265
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial.
Koren MJ; Giugliano RP; Raal FJ; Sullivan D; Bolognese M; Langslet G; Civeira F; Somaratne R; Nelson P; Liu T; Scott R; Wasserman SM; Sabatine MS;
Circulation; 2014 Jan; 129(2):234-43. PubMed ID: 24255061
[TBL] [Abstract][Full Text] [Related]
3. Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study.
Koren MJ; Sabatine MS; Giugliano RP; Langslet G; Wiviott SD; Kassahun H; Ruzza A; Ma Y; Somaratne R; Raal FJ
JAMA Cardiol; 2017 Jun; 2(6):598-607. PubMed ID: 28291870
[TBL] [Abstract][Full Text] [Related]
4. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
[TBL] [Abstract][Full Text] [Related]
5. Persistent Safety and Efficacy of Evolocumab in Patients with Statin Intolerance: a Subset Analysis of the OSLER Open-Label Extension Studies.
Cho L; Dent R; Stroes ESG; Stein EA; Sullivan D; Ruzza A; Flower A; Somaratne R; Rosenson RS
Cardiovasc Drugs Ther; 2018 Aug; 32(4):365-372. PubMed ID: 30073585
[TBL] [Abstract][Full Text] [Related]
6. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial.
Raal FJ; Stein EA; Dufour R; Turner T; Civeira F; Burgess L; Langslet G; Scott R; Olsson AG; Sullivan D; Hovingh GK; Cariou B; Gouni-Berthold I; Somaratne R; Bridges I; Scott R; Wasserman SM; Gaudet D;
Lancet; 2015 Jan; 385(9965):331-40. PubMed ID: 25282519
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study.
Raal FJ; Hovingh GK; Blom D; Santos RD; Harada-Shiba M; Bruckert E; Couture P; Soran H; Watts GF; Kurtz C; Honarpour N; Tang L; Kasichayanula S; Wasserman SM; Stein EA
Lancet Diabetes Endocrinol; 2017 Apr; 5(4):280-290. PubMed ID: 28215937
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia.
Kastelein JJ; Hovingh GK; Langslet G; Baccara-Dinet MT; Gipe DA; Chaudhari U; Zhao J; Minini P; Farnier M
J Clin Lipidol; 2017; 11(1):195-203.e4. PubMed ID: 28391886
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study.
Gaudet D; Langslet G; Gidding SS; Luirink IK; Ruzza A; Kurtz C; Lu C; Somaratne R; Raal FJ; Wiegman A
J Clin Lipidol; 2018; 12(5):1199-1207. PubMed ID: 30318065
[TBL] [Abstract][Full Text] [Related]
10. One-Year Efficacy and Safety of Evolocumab in Japanese Patients - A Pooled Analysis From the Open-Label Extension OSLER Studies.
Hirayama A; Yamashita S; Inomata H; Kassahun H; Cyrille M; Ruzza A; Yoshida M; Kiyosue A; Ma Y; Teramoto T
Circ J; 2017 Jun; 81(7):1029-1035. PubMed ID: 28367845
[TBL] [Abstract][Full Text] [Related]
11. Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
Arca M
Atherosclerosis; 2017 Jan; 256():134-145. PubMed ID: 27993383
[TBL] [Abstract][Full Text] [Related]
12. Impact of evolocumab treatment on low-density lipoprotein cholesterol levels in heterozygous familial hypercholesterolemic patients withdrawing from regular apheresis.
Kawashiri MA; Nohara A; Higashikata T; Tada H; Nakanishi C; Okada H; Konno T; Sakata K; Hayashi K; Inazu A; Mabuchi H; Yamagishi M
Atherosclerosis; 2017 Oct; 265():225-230. PubMed ID: 28926730
[TBL] [Abstract][Full Text] [Related]
13. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia.
Stein EA; Honarpour N; Wasserman SM; Xu F; Scott R; Raal FJ
Circulation; 2013 Nov; 128(19):2113-20. PubMed ID: 24014831
[TBL] [Abstract][Full Text] [Related]
14. Evolocumab Treatment in Pediatric Patients With Homozygous Familial Hypercholesterolemia: Pooled Data From Three Open-Label Studies.
Raal FJ; Hegele RA; Ruzza A; López JAG; Bhatia AK; Wu J; Wang H; Gaudet D; Wiegman A; Wang J; Santos RD
Arterioscler Thromb Vasc Biol; 2024 May; 44(5):1156-1164. PubMed ID: 38545781
[TBL] [Abstract][Full Text] [Related]
15. Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia.
Santos RD; Ruzza A; Hovingh GK; Wiegman A; Mach F; Kurtz CE; Hamer A; Bridges I; Bartuli A; Bergeron J; Szamosi T; Santra S; Stefanutti C; Descamps OS; Greber-Platzer S; Luirink I; Kastelein JJP; Gaudet D;
N Engl J Med; 2020 Oct; 383(14):1317-1327. PubMed ID: 32865373
[TBL] [Abstract][Full Text] [Related]
16. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.
Stroes E; Colquhoun D; Sullivan D; Civeira F; Rosenson RS; Watts GF; Bruckert E; Cho L; Dent R; Knusel B; Xue A; Scott R; Wasserman SM; Rocco M;
J Am Coll Cardiol; 2014 Jun; 63(23):2541-2548. PubMed ID: 24694531
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.
Raal FJ; Honarpour N; Blom DJ; Hovingh GK; Xu F; Scott R; Wasserman SM; Stein EA;
Lancet; 2015 Jan; 385(9965):341-50. PubMed ID: 25282520
[TBL] [Abstract][Full Text] [Related]
18. Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial.
Dufour R; Hovingh GK; Guyton JR; Langslet G; Baccara-Dinet MT; Din-Bell C; Manvelian G; Farnier M
J Clin Lipidol; 2019; 13(1):138-147. PubMed ID: 30591415
[TBL] [Abstract][Full Text] [Related]
19. Effect of the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Evolocumab on Glycemia, Body Weight, and New-Onset Diabetes Mellitus.
Sattar N; Toth PP; Blom DJ; Koren MJ; Soran H; Uhart M; Elliott M; Cyrille M; Somaratne R; Preiss D
Am J Cardiol; 2017 Nov; 120(9):1521-1527. PubMed ID: 28844508
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Evolocumab in Patients With Familial Hypercholesterolemia.
Santos RD; Stein EA; Hovingh GK; Blom DJ; Soran H; Watts GF; López JAG; Bray S; Kurtz CE; Hamer AW; Raal FJ
J Am Coll Cardiol; 2020 Feb; 75(6):565-574. PubMed ID: 32057369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]